GT
BMY.RT

Glenmede Trust’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Glenmede Trust’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-157,911
Closed -$107K – 1284
2020
Q4 		$107K Sell
157,911
-220,834
-58% -$470K ﹤0.01% 1100
2020
Q3 		$852K Sell
378,745
-740,084
-66% -$2.11M 0.01% 652
2020
Q2 		$4M Sell
1,118,829
-75,834
-6% -$274K 0.02% 397
2020
Q1 		$3.6M Hold
1,194,663
– – 0.02% 519
2019
Q4 		$3.6M Buy
+1,194,663
New +$3.11M 0.02% 519

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Glenmede Trust's BMY.RT Position: Q1 2021 in Review

Glenmede Trust sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 157,911 shares — an estimated $107K sold.

Glenmede Trust first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $4M in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Glenmede Trust reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Glenmede Trust sold 157,911 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $107K.
  • Glenmede Trust first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Glenmede Trust's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $4M in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Glenmede Trust's 13F filing for Q1 2021, filed 18 May 2021.